Establishing a suspension culture-based lentiviral vector bioprocessing facility

Published: 10 March 2020
Interview
Gabrielle Humphrey
Gabrielle Humphrey
GABRIELLE HUMPHREY, Associate Director is the lead of the Vector Manufacturing Science and Technology group at Adaptimmune, UK. In 2018, Gabrielle established the team responsible for starting-up Adaptimmune’s manufacturing capabilities at the Catapult CGT Manufacturing Centre in Stevenage. Her focus is currently on the production of GMP lentiviral vector for TCR T-cell therapy. Previously she has been involved in the GMP manufacturing of lentiviral vectors for CAR T-cell therapy and for gene therapy applications. Her area of expertise is the design and delivery of cleanroom bioprocesses for novel breakthrough therapies focusing on single-use disposable flow paths, aseptic processing and data monitoring.


Gabrielle Humphrey

Author title

Associate Director is the lead of the Vector Manufacturing Science and Technology group at Adaptimmune, UK. In 2018, Gabrielle established the team responsible for starting-up Adaptimmune’s manufacturing capabilities at the Catapult CGT Manufacturing Centre in Stevenage. Her focus is currently on the production of GMP lentiviral vector for TCR T-cell therapy. Previously she has been involved in the GMP manufacturing of lentiviral vectors for CAR T-cell therapy and for gene therapy applications. Her area of expertise is the design and delivery of cleanroom bioprocesses for novel breakthrough therapies focusing on single-use disposable flow paths, aseptic processing and data monitoring.


Read now